Multi-scale machine learning model predicts muscle and functional disease progression

Machine Learning


  • Denny, A. P. & Heather, A. K. Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature. Oxid Med Cell Longev 7020295 (2017). (2017).

  • Andersen, G. et al. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J. Neurol. 264, 438–447 (2017).

    PubMed 

    Google Scholar 

  • Dahlqvist, J. R. et al. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. J. Neurol. 266, 1127–1135 (2019).

    PubMed 

    Google Scholar 

  • Dahlqvist, J. R. et al. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy. Neurology 95, e1211–e1221 (2020).

    CAS 
    PubMed 

    Google Scholar 

  • Fatehi, F. et al. Long-term follow-up of MRI changes in thigh muscles of patients with facioscapulohumeral dystrophy: A quantitative study. PLoS One. 12, e0183825 (2017).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Ferguson, M. R. et al. MRI change metrics of facioscapulohumeral muscular dystrophy: stir and T1. Muscle Nerve. 57, 905–912 (2018).

    CAS 
    PubMed 

    Google Scholar 

  • Friedman, S. D. et al. Longitudinal features of STIR bright signal in FSHD. Muscle Nerve. 49, 257–260 (2014).

    CAS 
    PubMed 

    Google Scholar 

  • Janssen, B. H. et al. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One. 9, e85416 (2014).

    ADS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Monforte, M. et al. Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging. J. Cachexia Sarcopenia Muscle. 10, 1258–1265 (2019).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang, L. H. et al. Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy. BMC Musculoskelet. Disord. 22, 262 (2021).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Han, J. J. et al. Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by kinect. Muscle Nerve. 51, 168–175 (2015).

    ADS 
    PubMed 

    Google Scholar 

  • Olsen, D. B., Gideon, P., Jeppesen, T. D. & Vissing, J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. J. Neurol. 253, 1437–1441 (2006).

    PubMed 

    Google Scholar 

  • Kan, H. E. et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 19, 357–362 (2009).

    PubMed 

    Google Scholar 

  • Kan, H. E. et al. Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR Biomed. 23, 563–568 (2010).

    CAS 
    PubMed 

    Google Scholar 

  • Friedman, S. D. et al. The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve. 45, 500–506 (2012).

    PubMed 

    Google Scholar 

  • Tasca, G. et al. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One. 7, e38779 (2012).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lareau-Trudel, E. et al. Muscle quantitative MR imaging and clustering analysis in patients with facioscapulohumeral muscular dystrophy type 1. PLoS One. 10, e0132717 (2015).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Leung, D. G., Carrino, J. A., Wagner, K. R. & Jacobs, M. A. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy. Muscle Nerve. 52, 512–520 (2015).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Mul, K. et al. Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers. J. Neurol. 265, 2646–2655 (2018).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang, L. H. et al. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD. Hum. Mol. Genet. 28, 476–486 (2019).

    PubMed 

    Google Scholar 

  • Heskamp, L., Ogier, A., Bendahan, D. & Heerschap, A. Whole-muscle fat analysis identifies distal muscle end as disease initiation site in facioscapulohumeral muscular dystrophy. Commun. Med. (Lond). 2, 155 (2022).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mellion, M. L. et al. Quantitative muscle analysis in FSHD using Whole-Body Fat-Referenced MRI: composite scores for longitudinal and Cross-sectional analysis. Neurology 99, e877–e889 (2022).

    CAS 
    PubMed 

    Google Scholar 

  • Widholm, P. et al., Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability. Muscle Nerve (2022).

  • Riem, L. et al. AI driven analysis of MRI to measure health and disease progression in FSHD. Sci. Rep. 14, 15462 (2024).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dijkstra, J. N. et al. Natural history of facioscapulohumeral dystrophy in children: A 2-Year Follow-up. Neurology 97, e2103–e2113 (2021).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Woodcock, I. R., de Valle, K., Varma, N., Kean, M. & Ryan, M. M. Correlation between whole body muscle MRI and functional measures in paediatric patients with facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 33, 15–23 (2023).

    PubMed 

    Google Scholar 

  • Willcocks, R. J. et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort. Ann. Neurol. 79, 535–547 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sampson, J. H. et al., MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. J Clin. Oncol 38 (2020).

  • Zhou, N. & Manser, P. Does including machine learning predictions in ALS clinical trial analysis improve statistical power? Ann. Clin. Transl Neurol. 7, 1756–1765 (2020).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. & Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin. Drug Discov. 19, 33–42 (2024).

    CAS 
    PubMed 

    Google Scholar 

  • Wong, C. J. et al., Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression. Hum Mol. Genet (2024).

  • Ni, R., Meyer, C. H., Blemker, S. S., Hart, J. M. & Feng, X. Automatic segmentation of all lower limb muscles from high-resolution magnetic resonance imaging using a cascaded three-dimensional deep convolutional neural network. J. Med. Imaging (Bellingham). 6, 044009 (2019).

    PubMed 

    Google Scholar 

  • Santago, A. C. 2 Quantitative analysis of Three-Dimensional distribution and clustering of intramuscular fat in muscles of the rotator cuff. Ann. Biomed. Eng. 44, 2158–2167 (2016)., et al.

    PubMed 

    Google Scholar 

  • Chang, R. et al. Percentage fat fraction in magnetic resonance imaging: upgrading the osteoporosis-detecting parameter. BMC Med. Imaging. 20, 30 (2020).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Hothorn, T. & Jung, H. H. RandomForest4Life: a random forest for predicting ALS disease progression. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 444–452 (2014).

    PubMed 

    Google Scholar 

  • Ko, K. D., El-Ghazawi, T., Kim, D. & Morizono, H. & Pooled Resource Open-Access, A.L.S.C.T.C. Predicting the severity of motor neuron disease progression using electronic health record data with a cloud computing Big Data approach. IEEE Symp Comput Intell Bioinforma Comput Biol Proc 2014 (2014).

  • Lundberg, S. M. & Lee, S. I. A unified approach to interpreting model predictions. Adv Neur in 30 (2017).

  • Ponce-Bobadilla, A. V., Schmitt, V., Maier, C. S., Mensing, S. & Stodtmann, S. Practical guide to SHAP analysis: explaining supervised machine learning model predictions in drug development. Clin. Transl Sci. 17, e70056 (2024).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang, L. H., Johnstone, L. M., Bindschadler, M., Tapscott, S. J. & Friedman, S. D. Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report. BMC Musculoskelet. Disord. 22, 56 (2021).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Colelli, G. et al. Radiomics and machine learning applied to STIR sequence for prediction of quantitative parameters in facioscapulohumeral disease. Front. Neurol. 14, 1105276 (2023).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Fatehi, F., Salort-Campana, E., Le Troter, A., Bendahan, D. & Attarian, S. Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach. Rev. Neurol. (Paris). 172, 566–571 (2016).

    CAS 
    PubMed 

    Google Scholar 

  • Ferguson, M. R. et al. Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients. Neurology 87, 1746 (2016).

    PubMed 

    Google Scholar 

  • Fionda, L. et al., Comparison of quantitative muscle ultrasound and whole-body muscle MRI in facioscapulohumeral muscular dystrophy type 1 patients. Neurol Sci (2023).

  • Mul, K. et al. Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology 89, 2057–2065 (2017).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Tasca, G. et al. Upper girdle imaging in facioscapulohumeral muscular dystrophy. PLoS One. 9, e100292 (2014).

    ADS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vincenten, S. C. C. et al. Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: the link to clinical outcome. J. Cachexia Sarcopenia Muscle. 14, 1695–1706 (2023).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wong, C. J. et al. Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression. Hum. Mol. Genet. 33, 698–708 (2024).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wong, C. J. et al. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. Hum. Mol. Genet. 29, 1030–1043 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Frisullo, G. et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J. Clin. Immunol. 31, 155–166 (2011).

    CAS 
    PubMed 

    Google Scholar 

  • Greco, A. et al. IL-6 and TNF are potential inflammatory biomarkers in facioscapulohumeral muscular dystrophy. J. Neuromuscul. Dis. 11, 327–347 (2024).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Tasca, G. et al. Muscle Microdialysis to investigate inflammatory biomarkers in facioscapulohumeral muscular dystrophy. Mol. Neurobiol. 55, 2959–2966 (2018).

    CAS 
    PubMed 

    Google Scholar 

  • Blaszczyk, E. et al. Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: a cardiovascular magnetic resonance follow-up study. J. Cardiovasc. Magn. Reson. 23, 130 (2021).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350, g7594 (2015).

    PubMed 

    Google Scholar 



  • Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *